Oncology
Conference Coverage
High-quality index colonoscopies pay off down the road for low-risk patients
Later risk for advanced adenomas, serrated polyps, or colorectal cancer was lower for patients with an initial high-quality colonoscopy.
Feature
$38,398 for a single shot of a very old cancer drug
The first issue is unrelenting price increases on old drugs that have remained branded as manufacturers find ways to extend patents for decades...
Feature
‘Financial toxicity’: Harsh side effect of cancer care
High costs of cancer treatment can induce more anxiety and distress than the treatment itself.
From the Journals
Study affirms better breast cancer outcomes when chemo comes first
Survival is better when high-risk breast cancer patients receive chemo first, followed by abemaciclib and estrogen therapy.
From the Journals
Vitamin D deficiency linked to death, new study finds
A genetic approach provides support for the effects of vitamin D on mortality. The benefits of vitamin D supplementation are largely found in...
Conference Coverage
EUS-guided RF ablation doubles survival for unresectable pancreatic cancer
Endoscopic ultrasound–guided radiofrequency ablation of tumors improved overall survival compared with standard of care.
From the Journals
Durvalumab combinations show tentative promise in NSCLC
Phase 2 study indicates improved survival and objective response rate when combined with other immunotherapies.
Conference Coverage
Pancreatic cancer screening appears safe, effective for high-risk patients
The study explored a targeted strategy for screening since pancreatic cancer screening is not recommended for the general population.
News
FDA approves new immunotherapy combo for liver cancer
Latest News
Vaginal estrogen not recommended with aromatase inhibitors
“Patients who are taking aromatase inhibitors should try alternative strategies for management of genitourinary symptoms.”
From the Journals
Analysis suggests an ‘urgent need’ for personalized head and neck cancer follow-up
Assessment schedules should be individualized and evidence-based to assess cancer recurrence.